Skip directly to content

Ibrance® ▼ (palbociclib)

What is IBRANCE and what is it used for?

IBRANCE is indicated for the treatment of patients with HR+/HER2- locally advanced or mBC:1

•    In combination with an AI
•    In combination with fulvestrant, following relapse on endocrine therapy

In pre- or peri-menopausal women, endocrine therapy should be combined with an LHRH agonist.

Ibrance is a cancer medicine used to treat locally advanced or metastatic breast cancer (cancer that has begun to spread to other parts of the body). Ibrance can only be used when the cancer cells have receptors for certain hormones on their surface (HR-positive) and do not produce abnormally large quantities of a receptor called HER2 (HER [human epidermal growth factor] negative).2

The active substance in Ibrance, palbociclib, blocks the activity of enzymes known as cyclin-dependent kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide. In some cancers, including HR-positive breast cancer, the activity of CDK 4 and 6 is increased, which helps the cancer cells to multiply uncontrollably. By blocking CDK4 and CDK6, Ibrance slows the growth of HR-positive breast cancer cells.2

The medicine can only be obtained with a prescription.

 

Reference information
  • The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. One of the ways they do this is by producing evidence based guidance. See NICE guidance on IBRANCE
  • The European Medicines Agency (EMA) is an agency of the European Union (EU), located in London. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on IBRANCE
  • If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for IBRANCE these can be found at the electronic Medicines Compendium (eMC)

 

References

  1. Pfizer. IBRANCE Summary of Product Characteristics. February 2018.
  2. European Medicines Agency. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici...

 

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

PP-IBR-GBR-0743 | May 2018